SaurabhDahiyaMD

Oncology • Stanford, CA

Hematologic Oncology

Fellow

Join to view full profile

Dr. Dahiya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dahiya's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000
Is this information wrong?

Education & Training

UMass Chan - BaystateFellowship, Hematology and Medical Oncology, 2013 - 2016
UMass Chan - BaystateResidency, Internal Medicine, 2010 - 2012
Western Reserve Health Education/NEOMEDInternship, Internal Medicine, 2009 - 2010
Maulana Azad Medical CollegeClass of 2008

Certifications & Licensure

CA State Medical License 2016 - 2025
MD State Medical License 2017 - 2022
MA State Medical License 2014 - 2018
OH State Medical License 2009 - 2014

Publications & Presentations

PubMed

6 citations
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy
Khushali Jhaveri, Ilana Schlam, Noa G. Holtzman, Monica Peravali, Perry K. Richardson
Blood Advances. 2020-12-08
1208 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20
443 citations
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi
Journal of Clinical Oncology. 2020-05-13

Abstracts/Posters

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018